# Deposition of Inhaled Prolastin in Cystic Fibrosis Patients

> **NCT00486837** · PHASE2 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 72 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Alpha1-Proteinase Inhibitor (Human)

## Key facts

- **NCT ID:** NCT00486837
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486837, "Deposition of Inhaled Prolastin in Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00486837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*